BMO Capital Weighs in on OncoMed Pharmaceuticals (OMED) Following Abstracts at AACR
Tweet Send to a Friend
BMO Capital analyst Jim Birchenough reiterated an Outperform rating and $43 price target on OncoMed Pharmaceuticals (NASDAQ: OMED) abstracts were ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
